Navigation Links
Kinex Pharmaceuticals' Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Society's 2013 Honoree for its Cuisine for a Cure event
Date:4/12/2013

BUFFALO, N.Y., April 12, 2013 /PRNewswire/ -- Kinex Pharmaceuticals announced that Dr. David Hangauer , co-founder and Chief Scientific Officer of Kinex, has been named the American Cancer Society's 2013 Honoree of the year for its Cuisine for a Cure event. 

"I am honored to be the 2013 honoree for the American Cancer Society Cuisine for a Cure event.  I have devoted much of my career to discovering better drugs for treating cancer, two of which have recently advanced to clinical trials.  Through these efforts I am constantly humbled by the courage and strength of the cancer patients.  To be able to work on such an important medical need is a privilege," said Dr. David Hangauer .

"Kinex was initially founded upon a scientific platform to develop better drugs for treating cancer.  This is not solely a professional endeavor for us.  Importantly, our company is driven by a deep personal commitment as we have all been touched by both the devastation of cancer and the hope and extended life that new compounds can bring when fighting the disease.  Dave is the foundation of our efforts in Kinex.  Progress in treatment regimens will continue as extremely productive and engaged scientists like Dr. David Hangauer lead the charge in the fight against cancer," quoted Dr. Allen Barnett , President Emeritus of Kinex. 

Dr. Johnson Lau , CEO of Kinex, commented, "Both patients and Kinex are fortunate to have Dr. Hangauer dedicated to the field of cancer.  His expertise in drug discovery, coupled with tireless effort and commitment, has generated two very promising novel compounds for the treatment of various tumor types that Kinex and our drug development partners, Hanmi Pharmaceuticals, Xiangxue Pharmaceuticals, and PharmaEssentia are actively pursuing.  His focus on improving patient's lives through the discovery and development of new and better drugs is well reflected by the recognition of his achievements at the American Cancer Society 2013 event.  Kinex is proud to have Dave as our cofounder and Chief Scientific Officer."

Kinex Inquiries:

Patrick Gallagher
Vice President, Business Development and Investor Relations
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
pgallagher@kinexpharma.com


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
2. Kinex Pharmaceuticals Receives Substantial Strategic Investment
3. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
4. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):